Stopping sepsis by targeting sphingosine kinase 1.
Each year, more than a half million people in the United States alone die from sepsis, a dire multisystem disease with highly inadequate treatment options. In a recent issue of Science, Puneet and colleagues provide compelling evidence that inhibiting sphingosine kinase 1--an enzyme that resides in immune cells and is activated by inflammatory signals--might have great potential as a therapy for septic shock.
O'Neill
Luke A J
LA
School of Biochemistry and Immunology, Trinity College, Dublin, Ireland. laoneill@tcd.ie
D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018805:Sepsis / Q000188:drug therapy / Q000201:enzymology*; D015398:Signal Transduction / Q000187:drug effects; D000099157:Sphingosine Kinase
D004791:Enzyme Inhibitors; D017853:Phosphotransferases (Alcohol Group Acceptor); D000099157:Sphingosine Kinase